Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings and target prices for Monte Rosa Therapeutics and Dyadic International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 0 | 1 | 3 | 0 | 2.75 |
| Dyadic International | 0 | 0 | 1 | 0 | 3.00 |
Monte Rosa Therapeutics presently has a consensus price target of $17.75, indicating a potential upside of 153.93%. Dyadic International has a consensus price target of $6.00, indicating a potential upside of 210.88%. Given Dyadic International’s stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Monte Rosa Therapeutics.
Risk & Volatility
Institutional & Insider Ownership
80.5% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 15.4% of Dyadic International shares are owned by institutional investors. 5.3% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 27.3% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Monte Rosa Therapeutics and Dyadic International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | N/A | -42.09% | -33.94% |
| Dyadic International | -251.43% | -68.23% | -55.62% |
Valuation & Earnings
This table compares Monte Rosa Therapeutics and Dyadic International’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | N/A | N/A | -$108.50 million | ($2.43) | -2.88 |
| Dyadic International | $2.93 million | 18.98 | -$9.73 million | ($0.28) | -6.89 |
Dyadic International has higher revenue and earnings than Monte Rosa Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Monte Rosa Therapeutics beats Dyadic International on 7 of the 13 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
